MARIPOSA: Amivantamab, Lazertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC

The panel reacts to the MARIPOSA trial, which looked at amivantamab, lazertinib, and chemotherapy in the front line in patients with EGFR-mutant non–small cell lung cancer.

Related Keywords

,Evolving Treatment Paradigm ,Advanced Non ,Small Cell Lung Cancer ,Non Small Cell Lung Cancer ,Nsclc ,Advanced Non Small Cell Lung Cancer ,Advanced Nsclc ,Nsclc Treatment ,Egfr Mutant Lung Cancer ,Egfr Mutated Lung Cancer ,First Line Treatment ,Mariposa Study ,Amivantamab ,Lazertinib ,